Skip to content
CancerIndex

Publication

A novel triple-knockout allogeneic BCMA CAR T-cell therapy (CT0590) for multiple myeloma: preclinical and phase 1 study.

Song Jin, Zhaohui Liao, Shuang Yan, Lingzhi Yan, Weiqin Yao, Jingjing Shang, Fang Tang, Ziling Zhu, Depei Wu, Nishanthan Rajakumaraswamy, Yi Luo, Daijing Yuan, Hua Jiang, Zonghai Li, Chengcheng Fu

BloodSep 3, 2026PMID 42275247doi:10.1182/blood.2025032112 Journal ArticleClinical Trial, Phase IpubmedProvenance
Source
PubMed
Retrieved
Sep 29, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260929-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Host-versus-graft reaction (HVGR) is a major challenge in allogeneic chimeric antigen receptor (CAR) T-cell therapy. To counter host natural killer (NK) cell attacks, we armored allogeneic, HLA-I-deficient, B-cell maturation antigen (BCMA)-targeting CAR T cells with an NKG2A CAR. In vitro and…

Read on PubMed

Linked entities

Linked entities (2)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 1

Candidate 1

Registered trialsNCT05066022

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.